September 19, 2016 08:22 AM EDT

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

Arsalan Arif

Founder and CEO

San Diego-based Vical $VICL says that its lead vaccine ASP0113 flopped in a Phase II study designed to thwart herpes in kidney transplant patients. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

Arsalan Arif

Founder and CEO

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

A new dawn for psychedelics? Compass could be the first to find out

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Weeks after TIGIT fail, iTeos decides to wind down

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

Founder and CEO

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lead vaccine from Vical and Astellas flops in a Phase II herpes study